CarboHyde noted that the FDA included a 30:70 NHDC/γ-cyclodextrin inclusion complex in GRN 1292, highlighting complexation changes in solubility, absorption, and bioavailability.

CarboHyde is a cyclodextrin expert company working across pharmaceutical, biotechnology, cosmetic, and industrial applications to solve complex formulation challenges. We're a team of cyclodextrin specialists who saw the gap between what's possible with these molecules and what's actually being done in industry. While cyclodextrins are used in over 130 approved pharmaceuticals, we believe their potential goes far beyond current applications, and we're here to unlock it. What sets us apart is the comprehensive cyclodextrin expertise we deliver as an integrated service: chemistry, formulation development, analytical methods, GMP manufacturing, regulatory strategy and commercialization. We work in two ways: as a contract research organization (CRO) providing cyclodextrin solutions to companies facing formulation problems from custom synthesis to analytical support and regulatory consultation, while also educating the industry and advancing our own research programs in areas like rare diseases, neurodegenerative disorders, gene therapy, and vaccine development. Based in Budapest, with operations in India, we collaborate with leading universities and industry partners, including Janssen and Lonza, through major EU-funded projects such as GENEGUT and Bicyclos. Whether you need cyclodextrin expertise for a complex formulation, want to explore new delivery approaches, or are looking for specialized training, we're ready to work with you. 🌐 www.carbohyde.com